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METHODS: We compared baseline and 1-month post-
intervention scores from the SF-36 from two previously
reported study groups: headache patients at a headache
clinic (individualized therapy group) and headache suf-
ferers attending headache seminars at their workplaces
(education group). Research using the SF-36 determined
that the domains of role—physical, bodily pain, role—
emotional, and social functioning are most impacted by
chronic headache. For ethical reasons, the individualized
treatment group was not treated with education alone,
therefore their scores are shown for comparison only. No
statistical analysis was performed.
RESULTS: In this study 461 consecutive new patients
seeking headache care at the Cleveland Clinic Headache
Center were compared with 368 headache sufferers at-
tending headache seminars at their workplaces. Both
groups had similar ages, gender mix, and duration of
headache. The individualized therapy group had signifi-
cantly lower SF-36 scores at baseline.
CONCLUSIONS: The patient education component of
headache treatment has a measurable and clinically sig-
nificant impact on health-related quality of life as mea-
sured by the SF-36. Patient education appears to have as
significant a role as comprehensive treatment in the key
headache domain of role–emotional. In other mental
health domains, education alone appears to have a major
influence on improvement. In physical domains such as
bodily pain and role–physical, the impact of pharmaco-
logic therapy appears to have a greater impact.
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THE ECONOMIC COST OF ACETAMINOPHEN-
RELATED LIVER TOXICITY TO THE 
CALIFORNIA MEDICAID PROGRAM
Menzin J, deFriesse R, O’Donoghue S, Friedman M
Boston Health Economics, Inc., Billerica, MA, USA
Awareness of acetaminophen-related liver toxicity has
been growing. However, its frequency and cost have not
been well documented on a population basis. 
OBJECTIVE: To estimate the incidence and costs of
hepatotoxicity related to acetaminophen use for the Cali-
fornia Medicaid program (Medi-Cal). 
METHODS: This study was based on administrative
claims data for a 10% random sample of Medi-Cal recip-
ients in 1996. Individuals with one or more inpatient or
outpatient claims in 1996 with ICD-9-CM diagnoses of
acetaminophen-related liver toxicity were selected for in-
clusion in this analysis. An episode of treatment was de-
fined as the period of time between the dates of hospital
admission and discharge for which at least one qualifying
diagnosis was listed, or as a day of outpatient treatment
on which a patient had a qualifying diagnosis. All ser-
vices occurring during an episode were assumed to be re-
lated to acetaminophen liver toxicity.
RESULTS: A total of 244 recipients in our 10% sample
had one or more treatment episodes of acetaminophen-
related liver toxicity during 1996 (approximately 41 per-
sons per 100,000 eligibles), and over half of these oc-
curred in persons under 21 years of age. Approximately
20% of patients required admission to a hospital for
treatment. The average cost per patient with liver toxicity
was estimated to be approximately $1070. 
CONCLUSIONS: Based on our estimates of incidence
and per-person expenditures, annual spending by the
Medi-Cal program for acetaminophen-related hepatotox-
icity is projected to be approximately $2.6 million in
1996. The actual incidence of this problem is likely to be
greater than that reported here, since this study only in-
cludes poisonings that led to a medical encounter rather
than all possible occurrences.
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Measuring quality of life (QoL) has become a vital part
of assessing effects of migraine treatment in many inter-
national studies. However, only recently have measures
assessing patients’ perceptions of and satisfaction with
migraine treatment been available and none with linguis-
tically validated translations. Prior to use in an interna-
tional trial, the PPMQ (developed in US English) under-
went linguistic validation in 16 languages. 
METHODS: A QOL specialist coordinated the transla-
tion process of the PPMQ in each target country using
the following methodology: 1) two forward translations
by professional, native speaking translators of the target
language who were fluent in English; 2) comparison and
reconciliation of the translations by a QOL specialist and
translators; 3) backward translation by a native English
speaker; 4) comparison of the source and backward ver-
sion; 5) review of the translation by a clinician in each
country; 6) international harmonization. 
RESULTS: Linguistic, conceptual, and cultural issues
emerged when translating idiomatic phrases and response
scales. “How consistently the medication prevented pain
from coming back” had to be expressed through “reli-
ably” or “constantly.” Cultures less used to completing
questionnaires had difficulty understanding instructions
inviting respondents to express satisfaction with medica-
Change from baseline SF-36 score
Domain Education Individualized therapy
Physical functioning 0.3 2.5
Role–Physical 6.1 11.4
Bodily pain 3.9 9.1
General health 1.8 1.8
Vitality 4.4 2.8
Social functioning 5.5 9.2
Role–Emotional 7.5 7.5
Mental health 1.9 3.2
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tion in relation to subsequent statements, therefore appro-
priate clarifications had to be added. The response scale
“very completely, completely, average, incompletely, very
incompletely” was impossible to translate literally. The
following equidistant responses were substituted: “com-
pletely, quite a bit, average, a little bit, not at all.” 
CONCLUSIONS: A rigorous translation methodology
was performed to ensure conceptual equivalence and ac-
ceptability of translations. International feedback obtained
through the translation process revealed issues regarding
the original instrument, indicating that future amend-
ments to the original may be necessary. Psychometric test-
ing will be conducted to ensure reliability and validity of
each translation, appropriateness of the questionnaire in
each country, and comparability of data across countries.
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OBJECTIVE: The purpose of this study was to evaluate
prescribing of opioid analgesics for the treatment of non-
malignant pain conditions. 
METHODS: The 1995 MarketScan® database was used
to identify patients without malignant diagnoses and at
least one prescription for an opioid. The resulting cohort
was classified into three mutually exclusive categories:
transdermal fentanyl (TDF, n  118), long-acting opio-
ids (LA, n  136), and short-acting opioids (SA, n 
92,412). Demographics, diagnosis categories, and re-
source utilization (outpatient, inpatient, and prescription
claims) were examined. 
RESULTS: The number of patients in the SA group was
disproportionately larger than the other groups prevent-
ing a direct comparison. Their average age was 40 years,
primarily female, and 71% working full time. The most
common diagnosis category was musculoskeletal (MSK)
and lumbago was the most frequent condition. For com-
parative purposes, we examined diagnoses groups and re-
source utilization for the TDF and LA groups. Age, gen-
der, and employment status was similar for both groups.
The MSK category and lumbago diagnoses were also the
most common conditions. TDF patients had more lum-
bago physician visits but less cost/patient compared to
the LA group (median 6 visits, $49.50 versus 2.5 visits,
$74.50, respectively). Inpatient use was similar between
groups with a median of two occurrences/patient. The
median prescription use/patient of TDF was slightly less
than LA (3 versus 4.5) and both groups used a similar
number of other opioid analgesics (median  13).
CONCLUSION: This study suggests a similar distribu-
tion of conditions associated with the use of TDF, LA,
and SA opioids. However, SA opioid utilization in non-
malignant pain differs from TDF and LA agents. Further
analysis is necessary to identify characteristics that differ-
entiate these groups.
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OBJECTIVE: The purpose of the study is to compare the
resource utilization and costs related to the total medical
care of Duragesic patients with those incurred by patients
who have been prescribed long-acting opioids. This ab-
stract focuses on the methodology utilized to select a
comparison group for the Duragesic patients.
METHODS: We identified all patients without cancer in
a New England insurer database with at least one pre-
scription for Duragesic from January 1, 1995 through
December 31, 1997. We required each patient to be en-
rolled 30 days prior to the prescription index date and
the ensuing 90 days, and to have drug benefits (n  420).
We similarly identified patients with at least one prescrip-
tion for a long-acting opioid (n  1239). We character-
ized the patients by age, gender, health services utilized,
costs incurred, diagnosis, and drugs dispensed in the 30
days prior the index date.
RESULTS: Duragesic and long-acting opioid patients
had similar distributions of age, sex, and inpatient and
outpatient diagnoses. For both groups, musculoskeletal/
connective tissue conditions were among the most fre-
quent diagnoses, and costs were highest in the month
preceding the first opioid dispensing, dropping by about
50% over the ensuing 90 days.
CONCLUSIONS: Patterns of health resource utilization
and cost are similar for the two groups. Total costs incurred
are highest in the 30 days prior to the initial dispensing and
drop considerably during the following 90 days. There is
overlap among the non-malignant conditions treated with
Duragesic and long-acting opioids. These results suggest
that it may be possible to identify a useful and appropriate
comparison group for the Duragesic patients.
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